Salarius Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Twelve Months Ended December 31 | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Operating activities | |||
| Net loss | $(12,542,693) | $(31,607,956) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation, amortization and impairment | 10,051 | 6,677 | |
| Loss on Impairment of goodwill | — | 8,865,909 | |
| Equity-based compensation expense | 524,838 | 796,803 | |
| Grant receivable writeoff | 130,000 | ||
| Change in fair value of warrant liability | — | (14,454) | |
| In-process research and development technology | — | 1,987,900 | |
| Changes in operating assets and liabilities: | |||
| Grants receivable | 1,480,490 | — | |
| Prepaid expenses and other current assets | 807,770 | 202,538 | |
| Accounts payable | (2,255,477) | 1,312,735 | |
| Accrued expenses and other current liabilities | (1,001,116) | 854,527 | |
| Net cash (used in) operating activities | (12,846,137) | (17,595,321) | |
| Investing activities | |||
| Purchase in-process research and development technology | — | (1,500,000) | |
| Net cash used in investing activities | — | (1,500,000) | |
| Financing activities | |||
| Proceeds from issuance of equity securities | 6,920,529 | 1,987,376 | |
| Payments on note payable | (280,917) | — | |
| Net cash provided by financing activities | 6,639,612 | 1,987,376 | |
| Net decrease in cash, cash equivalents and restricted cash | (6,206,525) | (17,107,945) | |
| Cash, cash equivalents and restricted cash at beginning of period | 12,106,435 | 29,214,380 | |
| Cash, cash equivalents and restricted cash at end of period | $5,899,910 | $12,106,435 | |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $14,754 | $— | |
| Non-cash investing and financing activities: | |||
| Common stock issued for in-process research and development technology | $487,900 | ||
| Accrued cost for shares issued for cash | $2,500 | ||
| Insurance premium financed by note payable | $570,560 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.